Full-Time

Sr. Professional Education Manager

Remote USA

Posted on 9/5/2025

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$150k - $180k/yr

+ Base Salary + Variable incentive plan

Pleasanton, CA, USA

Hybrid

Category
Data & Analytics (4)
, , ,
Requirements
  • Bachelor’s Degree with 8 years of experience, or combined education/experience shall also be considered.
  • 5+ years in medical device industry
  • Additional 3+ years of demonstrated success in design and administration of professional education in the medical device industry
  • Strong proficiency in compliance and regulatory guidelines governing interactions with healthcare professionals (HCPs), industry events, and educational activities, including but not limited to AdvaMed Code of Ethics, Sunshine Act/Open Payments, fair market values, needs-based assessments, and grant support guidelines
  • Urology experience is a plus
  • Ability to travel 50-75%
  • Excellent interpersonal and negotiating skills; ability to adapt to changing work priorities
  • Polished communicator and presenter with excellent listening, teaching, and program evaluation skills.
  • Effective interpersonal interactions, both within the commercial group and in accounts
  • Proficiency with PC-based office computers, including familiarity with Microsoft Word, Excel, PowerPoint, and Outlook required
  • Ability to work independently
  • Valid driver's license
  • Compliance with relevant county, state, and Federal rules regarding vaccinations.
Responsibilities
  • Develop and execute effective education initiatives to drive market growth and adoption of Calyxo products with urologists and their staff
  • Manage all aspects of peer-to-peer educational events, including intake of requests, faculty selection tailored to audience needs, content selection, faculty preparation, and coordination of travel and logistics
  • Collaborate closely with the sales team to support peer-to-peer needs, including providing speaker bios, managing invitations, coordinating AV logistics, and ensuring adherence to HCP compliance and policy guidelines
  • Develop and refine peer-to-peer processes and resources to execute activities in a more efficient and effective manner
  • Conduct post-program evaluations of content and faculty performance, stay informed of changes that may affect training requirements, and proactively update training protocols and materials to reflect improvements
  • Collect and maintain post-event attendee lists, ensuring accurate documentation for reporting and follow up
  • Manage P2P budget, allocating funds based on goals and objectives
  • Develop and implement educational strategies using techniques such as e-learning, self-learning, web-based learning, experiential learning to meet the training needs.
  • Coordinate hands-on kidney model requests and support events requiring demos
  • Support academic initiatives for endourology fellows, residents, and emerging though leaders
  • Identify expert speakers who can deliver the defined curriculum as well as provide technical and clinical insight with real-world applications
  • Establish and manage physician faculty that drive Calyxo messaging with the urologists treating kidney stone disease
  • Manage HCP speaking and advisory contracts, faculty roster, travel, scheduling, invoicing, and reimbursement
  • Develop and maintains relationships with Calyxo faculty and KOLs in the endourology field
  • Proactively seek out and cultivate relationships with new healthcare providers who can help expand the brand's reach and influence.
  • Support faculty management by developing profiles and engagement/communication plans for each consultant
  • Assist with developing and executing the physician on-boarding and training curriculum
  • Translate business requirements into professional education programs through focused curriculum design, training event management, product training, and staff mentoring
  • Perform on-going comprehensive needs assessments to ensure professional education initiatives contribute and align with strategic priorities
  • Provide influence across the organization to secure support and resources to execute programs
  • Drive collaboration and partnership within cross-functional teams for professional education activities, commercial marketing events, and meetings
  • Participate in society meetings, forums, symposia, educational and scientific programming meetings for promoting product & procedural awareness and guideline development
  • Manage faculty honorarium, contracts, and budgeting in collaboration with other departments that utilize physician consultants and advisors (i.e., R&D, clinical/medical affairs, commercial and product marketing)
  • Identify and analyze professional education program metrics to measure effectiveness
  • Drive virtual education technology and strategic implementation with educational sites
  • May assume direct management responsibilities as the team expands or as future organizational needs are identified
Desired Qualifications
  • Urology experience is a plus

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Series F raised $40M led by Ally Bridge Group and Janus Henderson Investors.
  • CVAC system treated over 40,000 patients, advancing toward standard of care.
  • ASPIRE study at AUA showed superior clearance independent of stone burden in 101 patients.

What critics are saying

  • Boston Scientific's LithoClast Trilogy erodes market share via hospital contracts in 12-24 months.
  • Cook Medical's NGage basket undercuts CVAC pricing by 30% in 12-18 months.
  • FDA Class I recall triggers withdrawal due to 5% ureteral perforation risks in 3-9 months.

What makes Calyxo unique

  • CVAC System integrates ureteroscopy, laser lithotripsy, irrigation, and aspiration in one device.
  • SURE procedure with CVAC achieves 97% volumetric stone clearance versus standard URS.
  • Redesigned CVAC received FDA clearance in March 2024 for minimally invasive treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

INACTIVE